* SangStat Medical Corp., of Menlo Park, Calif., received FDAmarketing approval for Cross-Stat, a monitoring device used toidentify organ donors. The product was developed under a 1993agreement with Nextran Inc., a partnership between BaxterHealthcare Corp., of Deerfield, Ill., and DNX Corp., of Raritan, N.J.

* Cytogen Corp., of Princeton, N.J., started trials using OncoScintCR/OV, a monoclonal-based imaging agent, for preoperative stagingof breast cancer.

* Telios Pharmaceuticals Inc., of San Diego, said the U.S.Bankruptcy Court approved the company's proposed disclosurestatement for dissemination to shareholders.

* Digene Diagnostics Inc., of Silver Spring, Md., received FDAapproval for the Hybrid Capture System HPV DNA assay to helpidentify women at risk for developing high-grade cervical disease andcancer.

* DNA Plant Technology Corp., of Oakland, Calif., and Du Pont, ofWilmington, Del., finalized an agreement in which they willexchange rights to various technologies. Also, Du Pont agreed not tosell any DNAP stock it holds before March 1996. DNAP alsounveiled its second-generation version of a genetically modifiedtomato produced by selectable marker gene and promoter technology.

* Rhone-Poulenc Rorer Inc., of Collegeville, Pa., got regulatoryapproval in France for Campto, a topoisomerase 1 inhibitor, fortreatment of advanced colorectal cancer.

* Genetic Therapy Inc., of Gaithersburg, Md., started a Phase I/IItrial of a gene therapy treatment for Gaucher disease, in which anormal glucocerebrosidase gene will be incorporated into precursorblood cells removed from the patient.

* Aprogenex Inc., of Houston, said its first genetic testing product,the AproProbe research-use assay, is available for sale in Europe.

* Procept Inc., of Cambridge, Mass., completed a Phase I trial in theU.K. of its HIV drug candidate, PRO 2000. Initial data shows thedrug was well tolerated.

* Isis Pharmaceuticals Inc., of Carlsbad, Calif., said collaboratorCiba-Geigy Ltd., of Basel, Switzerland, accepted ISIS 5132/CGP69846 A as an early development compound. The antisenseoligonucleotide, which has shown activity against tumors in animalmodels, is expected to be taken into the clinic in 1996.

* Alexion Pharmaceuticals Inc., of Cambridge, Mass., unveiled a newclass of recombinant autoantigens, called Apogens, for the treatmentof multiple sclerosis.

* ImClone Systems Inc., of New York, initiated two Phase Ib/IIatrials of its lead cancer drug, C225, an epidermal growth factorreceptor antagonist.

* Univax Biologics Inc., of Rockville, Md., said it has made the firstsales of WinRho SD, a drug for immune thrombocytopenic purpura,to five regional distributors.

* Calgene Inc., of Davis, Calif., announced the successful harvest ofits first genetically engineered plant oils product, Laurate Canola.

* DNX Corp., of Raritan, N.J., and collaborators published data inthe May issue of the Journal of Lipid Research on the first transgenicmice that exhibit high LDL and low HDL cholesterol levels similar tohumans.

* AutoImmune Inc., of Lexington, Mass., and U.S. Bioscience Inc.,of West Conshohocken, Pa., separately announced the adoption ofshareholder rights plans.

* Medco Research Inc., of Research Triangle Park, N.C., andFujisawa USA Inc., of Deerfield, Ill., settled their respective lawsuits.Fujisawa will manufacture and market Adenoscan in the U.S. andCanada under a license from Medco.

* Neurobiological Technologies Inc., of Richmond, Calif., initiated asecond Phase I/II trial of corticotropin-releasing factor in asthmapatients.

* Mycogen Inc., of San Diego, said its Mycogen Plant Sciencessubsidiary sued Monsanto Co., of St. Louis, for alleged infringementof Mycogen's patent covering the process used to synthesize Btgenes.

(c) 1997 American Health Consultants. All rights reserved.

No Comments